



## Erratum

# Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” [Rev Bras Hematol Hemoter. 2016;38(4):346–357]



Celso Arrais Rodrigues<sup>a,b,\*</sup>, Matheus Vescovi Gonçalves<sup>a,c</sup>,  
Maura Rosane Valério Ikoma<sup>d</sup>, Irene Lorand-Metze<sup>e</sup>, André Domingues Pereira<sup>b</sup>,  
Danielle Leão Cordeiro de Farias<sup>f</sup>, Maria de Lourdes Lopes Ferrari Chauffaille<sup>a,c</sup>,  
Rony Schaffel<sup>g</sup>, Eduardo Flávio Oliveira Ribeiro<sup>h</sup>, Talita Silveira da Rocha<sup>i,j</sup>,  
Valeria Buccheri<sup>k</sup>, Yuri Vasconcelos<sup>l</sup>, Vera Lúcia de Piratinha Figueiredo<sup>m</sup>,  
Carlos Sérgio Chiattone<sup>j,n</sup>, Mihoko Yamamoto<sup>a</sup>, on behalf of the Brazilian Group of  
Chronic Lymphocytic Leukemia

<sup>a</sup> Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

<sup>b</sup> Hospital Sírio Libanês, São Paulo, SP, Brazil

<sup>c</sup> Fleury Medicina e Saúde, São Paulo, SP, Brazil

<sup>d</sup> Hospital Amaral Carvalho, Jaú, SP, Brazil

<sup>e</sup> Universidade Estadual de Campinas (UNICAMP), São Paulo, SP, Brazil

<sup>f</sup> Universidade Federal de Goiás (UFG), Goiânia, GO, Brazil

<sup>g</sup> Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil

<sup>h</sup> Hospital Santa Lúcia, Brasília, DF, Brazil

<sup>i</sup> A.C Camargo Cancer Center, São Paulo, SP, Brazil

<sup>j</sup> Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil

<sup>k</sup> Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil

<sup>l</sup> Instituto Goiano de Oncologia e Hematologia (INGOH), Goiânia, GO, Brazil

<sup>m</sup> Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, Brazil

<sup>n</sup> Hospital Samaritano, São Paulo, SP, Brazil

In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:

2) Relapsed first-line treatment:

- a) Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)

DOI of original article: <http://dx.doi.org/10.1016/j.bjhh.2016.07.004>.

\* Corresponding author at: Universidade Federal de São Paulo (UNIFESP), Rua Doutor Diogo de Faria, 824, Vila Clementino, 04037-002 São Paulo, SP, Brazil.

E-mail address: [celsorarrais@gmail.com](mailto:celsorarrais@gmail.com) (C.A. Rodrigues).

<http://dx.doi.org/10.1016/j.bjhh.2017.01.002>

1516-8484/© 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.

- b) Progress within 24 months:
- 'Go-go' patients: ibrutinib
  - Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab
  - 'Slow-go' patients: ibrutinib
  - Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite